Daewon Pharmaceutical said it has entered into a strategic partnership with Bayer Korea to exclusively distribute and market two of Bayer’s hormone replacement therapies (HRT) in Korea.

Under the partnership, Daewon will take over the sales and marketing of Angeliq (ingredient: drospirenone/estradiol hemihydrate) and Climen (ingredient: estradiol valerate/cyproterone acetate), two HRT medications prescribed for postmenopausal women.

Daewon Pharmaceutical will begin exclusive distribution, sales, and promotional activities for both products starting June 2, with Bayer Korea continuing to supply the medications.

These therapies are indicated for the treatment of estrogen deficiency symptoms in women more than one year after menopause and for the prevention of osteoporosis in postmenopausal women at increased risk of fractures.

Angeliq and Climen are widely used to alleviate common symptoms of menopause such as hot flashes, night sweats, sleep disturbances, and decreased bone density. According to IQVIA, a drug market research firm, the two products held a combined market share of approximately 30 percent in Korea’s hormone replacement therapy segment in 2024.

“We are proud to collaborate with Daewon Pharmaceutical, a company recognized for its strong commercial capabilities within Korea’s pharmaceutical industry,” Bayer Korea President Lee Jin-a said. “Through this partnership, we aim to improve access to effective menopause therapies and ultimately contribute to better quality of life for patients.”

Daewon Pharmaceutical CEO Baek In-hwan also said, “By combining Bayer Korea’s leadership in women’s health with Daewon’s proven market expertise, we expect to not only expand the reach of Angeliq and Climen but also strengthen collaboration between our two companies.”